Hypertension News and Research RSS Feed - Hypertension News and Research

New findings link obesity and dietary factors to late-life dementias

New findings link obesity and dietary factors to late-life dementias

Difficulties learning, remembering, and concentrating. An inability to resist environmental temptations to eat. A lifetime of progressive deterioration in the brain. [More]
Allscripts FollowMyHealth Achieve now available for patient engagement innovation

Allscripts FollowMyHealth Achieve now available for patient engagement innovation

Allscripts has announced the market launch and general availability of Allscripts FollowMyHealth Achieve, a consumer-friendly, patient engagement innovation intended to mobilize and empower patients as active partners in the management of their care. [More]
Temple researchers to create awareness about healthy diet among low-income Asian Americans

Temple researchers to create awareness about healthy diet among low-income Asian Americans

Although low-income Asian Americans are at a high risk for diabetes, hypertension, heart attack and stroke, they are under a misconception that their diet is healthy and not a risk factor for these chronic diseases. [More]
Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Boehringer Ingelheim today announced that Striverdi Respimat (olodaterol) Inhalation Spray 5 mcg is now available by prescription in pharmacies across the United States. [More]
Surgical treatment of strabismus can be carried out at any age

Surgical treatment of strabismus can be carried out at any age

Around four per cent of all newborn children have a squint. In about 50 per cent of cases, this can be corrected with appropriate glasses, however the other half require treatment for their squint and in some cases even squint surgery. [More]
Case Western Reserve researcher lands Director's New Innovator Awards from NIH

Case Western Reserve researcher lands Director's New Innovator Awards from NIH

For the second consecutive year, a Case Western Reserve University School of Medicine researcher has landed one of the year's much-coveted Director's New Innovator Awards from the National Institutes of Health. Principal investigator Rong Xu, PhD, assistant professor of medical informatics, will receive $2,377,000 for five years, starting immediately, to initiate computational analysis of thousands of drugs and their effects. [More]
IRCM researchers discover mechanism that promotes progression of medulloblastoma

IRCM researchers discover mechanism that promotes progression of medulloblastoma

Scientists at the IRCM discovered a mechanism that promotes the progression of medulloblastoma, the most common brain tumour found in children. The team, led by Fr-d-ric Charron, PhD, found that a protein known as Sonic Hedgehog induces DNA damage, which causes the cancer to develop. [More]
Study uncovers new pathway for treating high blood pressure, heart failure

Study uncovers new pathway for treating high blood pressure, heart failure

New research by scientists at the University of Maryland School of Medicine and the Ottawa Heart Institute has uncovered a new pathway by which the brain uses an unusual steroid to control blood pressure. [More]
Research performed in anemic mice shows acetate stimulates the formation of red blood cells

Research performed in anemic mice shows acetate stimulates the formation of red blood cells

UT Southwestern Medical Center researchers seeking novel treatments for anemia found that giving acetate, the major component of household vinegar, to anemic mice stimulated the formation of new red blood cells. [More]
Par Pharmaceutical starts shipping generic version of Exforge

Par Pharmaceutical starts shipping generic version of Exforge

Par Pharmaceutical Companies, Inc. today announced that it has begun shipping all four strengths of amlodipine and valsartan tablets, the generic version of Novartis' Exforge. Par received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for amlodipine and valsartan and was granted 180 days of marketing exclusivity. [More]
Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). [More]
Targeted treatments may improve idiopathic PAH survival

Targeted treatments may improve idiopathic PAH survival

Patients with idiopathic pulmonary arterial hypertension may live longer if they are given targeted treatments than if they receive conventional management, researchers suggest. [More]
Noninvasive diagnosis ‘reliable’ for pulmonary hypertension diagnosis

Noninvasive diagnosis ‘reliable’ for pulmonary hypertension diagnosis

Doppler echocardiography has good accuracy relative to right heart catheterisation for detecting pulmonary hypertension, shows a large study. [More]
Cardiac arrhythmias pose risk in pulmonary hypertension patients

Cardiac arrhythmias pose risk in pulmonary hypertension patients

Supraventricular arrhythmias are common and usually cause clinical deterioration in patients with idiopathic pulmonary arterial hypertension, a study shows. [More]
Increasing prevalence of obstructive sleep apnea threatens public health and safety

Increasing prevalence of obstructive sleep apnea threatens public health and safety

Public health and safety are threatened by the increasing prevalence of obstructive sleep apnea, which now afflicts at least 25 million adults in the U.S., according to the National Healthy Sleep Awareness Project. Several new studies highlight the destructive nature of obstructive sleep apnea, a chronic disease that increases the risk of high blood pressure, heart disease, Type 2 diabetes, stroke and depression. [More]
EnteroMedics' CE Mark for Maestro System expanded to include management of Type 2 diabetes mellitus

EnteroMedics' CE Mark for Maestro System expanded to include management of Type 2 diabetes mellitus

EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that its CE Mark for the Maestro Rechargeable (RC) System for obesity was expanded to include the management of Type 2 diabetes mellitus through improved glycemic control. [More]
CVRx Barostim neo System receives CE Mark approval from NSAI for treatment of heart failure

CVRx Barostim neo System receives CE Mark approval from NSAI for treatment of heart failure

CVRx, Inc., a private medical device company, announced today it received CE Mark approval from the National Standards Authority of Ireland of the Barostim neo System for the treatment of heart failure. [More]
NIH-funded clinical trial aims to restore vision in people who have lost vision due to IIH

NIH-funded clinical trial aims to restore vision in people who have lost vision due to IIH

In an NIH-funded clinical trial, led at Saint Louis University by professor of ophthalmology Sophia Chung, M.D., researchers aim to bring sight back to those who have lost vision due to idiopathic intracranial hypertension. [More]
Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo, Ambit Biosciences enter into definitive merger agreement

Daiichi Sankyo Company, Ltd. (hereinafter Daiichi Sankyo) and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis. [More]
Gastric bypass surgery provides better results than gastric banding

Gastric bypass surgery provides better results than gastric banding

Gastric bypass surgery has better outcomes than gastric banding for long-term weight loss, controlling type 2 diabetes and high blood pressure, and lowering cholesterol levels, according to a new review by UT Southwestern Medical Center surgeons of nearly 30 long-term studies comparing the two types of bariatric procedures. [More]